Precision BioSciences, Inc.
PBGENE-HBV
HBV
Resolved
176days ago
Phase 2 readout · Jan 12, 2026
What's at stake
Phase 2 trial results for PBGENE-HBV in HBV are due Jan 12, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Additional biopsy data is expected in the first half of 2026 building upon the first clinical evidence of viral gene editing for PBGENE-HBV which was shared at AASLD.”